Key result
Viruses pseudotyped with Myomaker and Myomerger specifically deliver micro-Dystrophin to skeletal muscle in Duchenne mice.
Why the study?
The authors investigated whether muscle-specific cell fusogens Myomaker and Myomerger could functionally substitute for classical viral fusogens to fuse enveloped viruses to cells.
Pseudotyping enveloped viruses with mammalian muscle fusogens enables targeted gene delivery to skeletal muscle, offering a potential platform for treating muscular dystrophies.
Muscle fusogens enable muscle-targeted viral transduction in mice; leaves open whether this extends to safe, effective human gene therapy.
Entry of enveloped viruses into cells is mediated by fusogenic proteins that form a complex between membranes to drive rearrangements needed for fusion. Skeletal muscle development also requires membrane fusion events between progenitor cells to form multinucleated myofibers. Myomaker and Myomerger are muscle-specific cell fusogens, but do not structurally or functionally resemble classical viral fusogens. We asked if the muscle fusogens could functionally substitute for viral fusogens, despite their structural distinctiveness, and fuse viruses to cells. We report that engineering of Myomaker and Myomerger on the membrane of enveloped viruses leads to specific transduction of skeletal muscle. We also demonstrate that locally and systemically injected virions pseudotyped with the muscle fusogens can deliver micro-Dystrophin (μDys) to skeletal muscle of a mouse model of Duchenne muscular dystrophy. Through harnessing the intrinsic properties of myogenic membranes, we establish a platform for delivery of therapeutic material to skeletal muscle.
No takes yet. Share an insight, caveat, or question.
Hindi et al. (2023) studied Duchenne muscular dystrophy (preclinical model). Enveloped viruses pseudotyped with Myomaker and Myomerger vs. Bald-LVs or VSV-G-LVs was evaluated on Viral transduction of skeletal muscle cells. Enveloped viruses pseudotyped with the mammalian muscle fusogens Myomaker and Myomerger specifically transduced skeletal muscle cells and delivered micro-Dystrophin to a mouse model of Duchenne muscular dystrophy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: